Can a central pulmonary embolus cause a transient decrease in diffusing capacity of the lung for carbon monoxide (DLCO)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Central Pulmonary Embolus and DLCO Reduction

Yes, central pulmonary embolism causes a transient decrease in DLCO, though the reduction may persist longer than expected and is primarily driven by decreased membrane diffusing capacity (DM) rather than capillary blood volume (Vc).

Mechanism of DLCO Reduction

The pathophysiology involves both immediate and sustained components:

  • Acute phase: DLCO decreases significantly in all patients with acute PE 1, 2. The reduction correlates inversely with the central mass of embolism—meaning larger, more central emboli cause greater DLCO impairment 1.

  • Primary mechanism: The decrease is predominantly due to reduced membrane diffusing capacity (DM) rather than pulmonary capillary blood volume (Vc) 1. This suggests alveolar-capillary membrane dysfunction is the key pathophysiologic driver, not simply reduced perfused capillary bed.

  • Severity correlation: Studies demonstrate a highly significant correlation (r = 0.80; p < 0.001) between the degree of vascular obstruction and reduction in alveolar-capillary gas exchange 3.

Clinical Significance and Time Course

Important caveat: The term "transient" requires qualification, as DLCO reduction persists far longer than clinically apparent:

  • All patients with acute PE show DLCO below 75% of predicted at presentation, making it a useful screening test—a normal DLCO effectively excludes acute PE 2.

  • Recovery is incomplete: Despite modern anticoagulation treatment and normalization of V/Q scans within 3 months, DLCO remains significantly reduced at 7-month follow-up in most patients 1, 2. This persistent reduction occurs even when symptoms resolve and imaging normalizes.

  • Membrane component persists: DM remains significantly lower than healthy controls at 7 months (P = 0.001), particularly in patients with persistent right ventricular dysfunction 1.

Differential Impact by PE Location

Central versus peripheral PE shows distinct patterns:

  • Central/massive PE: Shows moderate DLCO reduction (-15% in single massive events, -10% even with cardiogenic shock) 4.

  • Recurrent microembolism: Paradoxically causes greater sustained DLCO impairment (-31%) with more pronounced reduction in vascular component (Vc decreased by 21%) 4. This suggests repetitive small emboli cause more permanent microvascular damage than single large central events.

Clinical Application

When evaluating suspected PE:

  • DLCO reduction is universal in acute PE but too variable in magnitude to predict severity 2.
  • The 2019 ESC Guidelines 5 note that pulmonary function tests at follow-up are "largely within normal limits" in most PE survivors, which appears to contradict research showing persistent DLCO abnormalities—highlighting that routine spirometry may miss the sustained diffusion impairment.
  • The guidelines recommend clinical evaluation at 3-6 months post-PE 5 but do not specifically advocate routine DLCO measurement, focusing instead on V/Q scanning for patients with persistent dyspnea.

Key pitfall: Do not assume DLCO normalization parallels clinical or radiographic improvement. The membrane component defect persists despite successful anticoagulation and clot resolution, explaining why some patients have ongoing exercise limitation with "normal" standard testing 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.